BackGenzyme Corp. files patent infringement suit against Dr Reddy’s
Genzyme alleges that Dr Reddy’s infringed patents of its cancer drug Mozobil on three counts
Premium(Priyanka Parashar/ Mint)
Hyderabad: Genzyme Corp., a fully-owned subsidiary of drug major Sanofi-Aventis, has filed a suit against Dr Reddy’s Laboratories Ltd (DRL) alleging that the Indian drug maker infringed patents of its blockbuster cancer drug Mozobil on three counts.
Mozobil (plerixafor injection) is a hematopoietic stem cell mobilizer indicated to patients with non-Hodgkin’s lymphoma (blood cancer) and multiple myeloma.
In its petition filed in the District Court of Delaware, Genzyme alleged that DRL intimated though a letter that it had submitted an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to engage in the commercial manufacture, importation, use, and sale of 20 mg/ml Plerixafor injection as a generic version of Mobozil drug.
While one of the patents of the drug would expire on 10 December 2018 while other two patents—patent ‘590’ and patent ‘102’ on 22 July 2023, the US drug maker said.
Genzyme sought the court to declare that DRL’s making, using, selling, offering to sell, or importing its Plerixafor ANDA Injection Product by DRL is infringement of one or more claims of the patents. According to Sanofi’s 2012 annual report, Mozobil contributed €96 million to its revenues. However, patent litigation against generic drug makers is common in US and the legal process will not have any significant implications on DRL, according to an industry expert.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
